ZA973653B - Pharmaceutical compositions. - Google Patents

Pharmaceutical compositions.

Info

Publication number: ZA973653B
Authority: ZA; South Africa
Prior art keywords: surfactant; propylene glycol; range; chain length; pharmaceutical compositions
Prior art date: 1996-04-26

Application number

ZA9703653A

Other languages

English (en)

Inventor

Elizabeth Anne Perry

Susan Gerrard Chandler

Josephine Joan Chri Ferdinando

Original Assignee

Scherer Ltd R P

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-04-26

Filing date

1997-04-25

Publication date

1997-11-19

1997-04-25 Application filed by Scherer Ltd R P filed Critical Scherer Ltd R P

1997-11-19 Publication of ZA973653B publication Critical patent/ZA973653B/xx

Links

239000008194 pharmaceutical composition Substances 0.000 title abstract 2
239000004094 surface-active agent Substances 0.000 abstract 4
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 abstract 2
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 abstract 2
235000014113 dietary fatty acids Nutrition 0.000 abstract 2
229940079593 drug Drugs 0.000 abstract 2
239000003814 drug Substances 0.000 abstract 2
229930195729 fatty acid Natural products 0.000 abstract 2
239000000194 fatty acid Substances 0.000 abstract 2
150000004665 fatty acids Chemical class 0.000 abstract 2
230000002209 hydrophobic effect Effects 0.000 abstract 2
239000003921 oil Substances 0.000 abstract 2
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 abstract 1
BHIZVZJETFVJMJ-UHFFFAOYSA-N 2-hydroxypropyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(C)O BHIZVZJETFVJMJ-UHFFFAOYSA-N 0.000 abstract 1
229920003171 Poly (ethylene oxide) Polymers 0.000 abstract 1
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical class CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract 1
239000004359 castor oil Substances 0.000 abstract 1
235000019438 castor oil Nutrition 0.000 abstract 1
229930182833 estradiol Natural products 0.000 abstract 1
125000005456 glyceride group Chemical group 0.000 abstract 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 abstract 1
239000003163 gonadal steroid hormone Substances 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
-1 polyoxyethylene Polymers 0.000 abstract 1
239000000186 progesterone Substances 0.000 abstract 1
229960003387 progesterone Drugs 0.000 abstract 1
229940026235 propylene glycol monolaurate Drugs 0.000 abstract 1
229960003604 testosterone Drugs 0.000 abstract 1
150000003626 triacylglycerols Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Endocrinology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Dispersion Chemistry (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

ZA9703653A 1996-04-26 1997-04-25 Pharmaceutical compositions. ZA973653B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB9608719.2A GB9608719D0 (en)	1996-04-26	1996-04-26	Pharmaceutical compositions

Publications (1)

Publication Number	Publication Date
ZA973653B true ZA973653B (en)	1997-11-19

Family

ID=10792737

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA9703653A ZA973653B (en)	1996-04-26	1997-04-25	Pharmaceutical compositions.

Country Status (12)

Country	Link
EP (1)	EP0904064B1 (de)
JP (1)	JP5088804B2 (de)
KR (1)	KR100511133B1 (de)
AT (1)	ATE207346T1 (de)
AU (1)	AU2707497A (de)
DE (1)	DE69707669T2 (de)
DK (1)	DK0904064T3 (de)
ES (1)	ES2164339T3 (de)
GB (1)	GB9608719D0 (de)
PT (1)	PT904064E (de)
WO (1)	WO1997040823A1 (de)
ZA (1)	ZA973653B (de)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2777784B1 (fr) *	1998-04-27	2004-03-19	Arepa	Composition pharmaceutique a base d'estrogene et de progesterone
US20040234472A1 (en)	2001-04-20	2004-11-25	Jackson John K.	Micellar drug delivery systems for hydrophobic drugs
ES2316350T3 (es)	1999-02-26	2009-04-16	SHIONOGI & CO., LTD.	Capsulas blandas masticables con propiedades mejoradas de administracion y procedimiento para producirlas.
US6294192B1 (en)	1999-02-26	2001-09-25	Lipocine, Inc.	Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6652880B1 (en)	1999-04-01	2003-11-25	R.P. Scherer Technologies, Inc.	Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants
GB9907715D0 (en) *	1999-04-01	1999-05-26	Scherer Corp R P	Pharmaceutical compositions
AU768537B2 (en) *	1999-04-01	2003-12-18	Merck Sharp & Dohme B.V.	Formulation comprising testosteron undecanoate and castor oil
US20030236236A1 (en) *	1999-06-30	2003-12-25	Feng-Jing Chen	Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
GB0000313D0 (en)	2000-01-10	2000-03-01	Astrazeneca Uk Ltd	Formulation
AU2001284772A1 (en) *	2000-08-10	2002-02-25	Delsys Pharmaceutical Corporation	Improved solid pharmaceutical dosage formulation of hydrophobic drugs
FR2818905A1 (fr) *	2000-12-28	2002-07-05	Cll Pharma	Compositions pharmaceutiques colloidales micellaires renfermant un principe actif lipophile
WO2003000295A2 (en)	2001-06-21	2003-01-03	Pfizer Products Inc.	Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors
WO2003002095A1 (fr) *	2001-06-28	2003-01-09	Chugai Seiyaku Kabushiki Kaisha	Preparation d'une micro-emulsion de type huile-eau
FR2832065B1 (fr) *	2001-11-13	2004-11-05	Besins Int Belgique	Composition pharmaceutique a base de progesterone micronisee son procede de preparation et ses utilisations
JO2505B1 (en)	2003-03-14	2009-10-05	باير شيرنغ فارما اكتنجيسيلشافت	Pharmacy methods and formulations for obtaining acceptable serum testosterone levels
CN1299686C (zh) *	2003-04-03	2007-02-14	上海医药工业研究院	黄体酮半固体骨架制剂的组合物
CN1774179A (zh) *	2003-04-17	2006-05-17	贝林格尔.英格海姆国际有限公司	供孕妇用的多种维生素及矿物质补充品
JP2005047851A (ja) *	2003-07-29	2005-02-24	Nisshin Pharma Inc	ユビデカレノン含有組成物
ATE319426T1 (de)	2003-11-11	2006-03-15	Mattern Udo	Nasenformulierung mit kontrollierter freisetzung von sexualhormonen
US8784869B2 (en)	2003-11-11	2014-07-22	Mattern Pharma Ag	Controlled release delivery system for nasal applications and methods of treatment
CA2604943C (en) *	2005-04-15	2013-09-17	Clarus Therapeutics, Inc.	Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
US8492369B2 (en)	2010-04-12	2013-07-23	Clarus Therapeutics Inc	Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
WO2008040488A1 (en)	2006-10-04	2008-04-10	M & P Patent Aktiengesellschaft	Controlled release delivery system for nasal application of neurotransmitters
EP1961412A1 (de)	2006-12-27	2008-08-27	LEK Pharmaceuticals D.D.	Selbstmikroemulgierende Arzneimittelabgabesysteme
GB0807605D0 (en) *	2008-04-28	2008-06-04	Diurnal Ltd	Lipid composition
AU2014200332B2 (en) *	2008-04-28	2016-10-06	Diurnal Limited	Lipid composition
WO2010042499A1 (en)	2008-10-06	2010-04-15	Banner Pharmacaps, Inc.	Stable solutions of orlistat for pharmaceutical dosage forms
KR101702142B1 (ko) *	2008-10-22	2017-02-03	아유미 세이야쿠 가부시키가이샤	장관 흡수성을 개선하는 의약 조성물
US11304960B2 (en)	2009-01-08	2022-04-19	Chandrashekar Giliyar	Steroidal compositions
WO2010117873A2 (en)	2009-04-06	2010-10-14	Banner Pharmacaps, Inc.	Progesterone solutions for increased bioavailability
CA2779005A1 (en) *	2009-11-09	2011-05-12	Capsugel Belgium Nv	Delivery carrier
PL2519230T3 (pl)	2009-12-31	2019-05-31	Marius Pharmaceuticals Llc	Modulacja rozpuszczalności, stabilności, absorpcji, metabolizmu i profilu farmakokinetycznego leków lipofilowych przez sterole
CN103705462B (zh) *	2010-04-12	2016-08-31	克劳拉斯医疗有限公司	口服睾酮酯制剂以及包含其的治疗睾酮缺乏症的方法
AU2010351080B2 (en) *	2010-04-12	2014-08-28	Besins Healthcare Luxembourg S.A.R.L.	Oral testosterone ester formulations and methods of treating testoterone deficiency comprising same
US9358241B2 (en)	2010-11-30	2016-06-07	Lipocine Inc.	High-strength testosterone undecanoate compositions
US20180153904A1 (en)	2010-11-30	2018-06-07	Lipocine Inc.	High-strength testosterone undecanoate compositions
US9034858B2 (en)	2010-11-30	2015-05-19	Lipocine Inc.	High-strength testosterone undecanoate compositions
US20120148675A1 (en)	2010-12-10	2012-06-14	Basawaraj Chickmath	Testosterone undecanoate compositions
US8900631B2 (en)	2011-04-28	2014-12-02	Health Science Funding, LLC	Dosage form to increase prasterone bioavailability
US9757388B2 (en)	2011-05-13	2017-09-12	Acerus Pharmaceuticals Srl	Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
AR086400A1 (es)	2011-05-13	2013-12-11	Trimel Pharmaceuticals Corp	Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo
US20130045958A1 (en)	2011-05-13	2013-02-21	Trimel Pharmaceuticals Corporation	Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US9301920B2 (en)	2012-06-18	2016-04-05	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
BR112014012444B1 (pt) *	2011-11-23	2021-12-14	Therapeuticsmd, Inc	Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
FR2988609B1 (fr) *	2012-03-30	2015-09-04	Commissariat Energie Atomique	Formulation pour l'hormonotherapie
EP3909586A1 (de)	2012-06-18	2021-11-17	TherapeuticsMD, Inc.	Lösliche östradiolkapsel zur vaginalen einführung
US10806697B2 (en)	2012-12-21	2020-10-20	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en)	2012-06-18	2020-10-20	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
US20130338122A1 (en)	2012-06-18	2013-12-19	Therapeuticsmd, Inc.	Transdermal hormone replacement therapies
FR2997627B1 (fr)	2012-11-08	2015-01-16	Hra Pharma Lab	Produit de co-micronisation comprenant de l'ulipristal acetate
US10471072B2 (en)	2012-12-21	2019-11-12	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en)	2012-12-21	2015-11-10	Therapeuticsmd, Inc.	Soluble estradiol capsule for vaginal insertion
US11266661B2 (en)	2012-12-21	2022-03-08	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en)	2012-12-21	2022-02-15	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en)	2012-12-21	2020-02-25	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en)	2012-12-21	2020-01-21	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US11744838B2 (en)	2013-03-15	2023-09-05	Acerus Biopharma Inc.	Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
EP2968137B1 (de) *	2013-03-15	2021-11-10	Marius Pharmaceuticals LLC	Emulsionsformulierungen
RU2016143081A (ru)	2014-05-22	2018-06-26	Терапьютиксмд, Инк.	Натуральные комбинированные гормонозаместительные составы и терапии
AU2015276321B2 (en) *	2014-06-17	2019-10-24	Merck Sharp & Dohme B.V.	Stable formulations of testosterone undecanoate
WO2016033549A2 (en)	2014-08-28	2016-03-03	Lipocine Inc.	(17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US9498485B2 (en)	2014-08-28	2016-11-22	Lipocine Inc.	Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US20160361322A1 (en)	2015-06-15	2016-12-15	Lipocine Inc.	Composition and method for oral delivery of androgen prodrugs
US10328087B2 (en)	2015-07-23	2019-06-25	Therapeuticsmd, Inc.	Formulations for solubilizing hormones
WO2017105512A1 (en)	2015-12-18	2017-06-22	Proinvet Innovations S.A.	Formulations and methods for controlling the reproductive cycle and ovulation
US9931349B2 (en)	2016-04-01	2018-04-03	Therapeuticsmd, Inc.	Steroid hormone pharmaceutical composition
KR20180123165A (ko) *	2016-04-01	2018-11-14	쎄러퓨틱스엠디, 인코퍼레이티드	스테로이드 호르몬 약제학적 조성물
US20170281647A1 (en) *	2016-04-01	2017-10-05	Therapeuticsmd, Inc.	Steroid hormone compositions in medium chain oils
US10286077B2 (en)	2016-04-01	2019-05-14	Therapeuticsmd, Inc.	Steroid hormone compositions in medium chain oils
US11559530B2 (en)	2016-11-28	2023-01-24	Lipocine Inc.	Oral testosterone undecanoate therapy
BR112020010519A2 (pt)	2017-11-27	2020-10-20	Umecrine Cognition Ab	formulação farmacêutica de oxima de 3¿lfa-etinil-3¿eta-hidroxiandrostan-17-ona
AU2019308326B2 (en)	2018-07-20	2025-07-31	Lipocine Inc.	Liver disease
CN113195061A (zh) *	2019-03-29	2021-07-30	积水化学工业株式会社	芯壳结构体、制剂、外用药、贴剂以及化妆品
US11564933B2 (en)	2019-04-12	2023-01-31	Tolmar, Inc.	Methods of treating testosterone deficiency
US12403146B2 (en)	2019-10-30	2025-09-02	Marius Pharmaceuticals, Inc.	Preferred oral testosterone undecanoate therapy to achieve testosterone replacement treatment
US12514862B2 (en) *	2020-02-05	2026-01-06	Neurocrine UK Limited	Testosterone containing pharmaceutical composition
US11633405B2 (en)	2020-02-07	2023-04-25	Therapeuticsmd, Inc.	Steroid hormone pharmaceutical formulations
WO2023057626A1 (en)	2021-10-08	2023-04-13	Chemo Research, S.L.	Oral pharmaceutical compositions of progesterone and estradiol

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9405304D0 (en) *	1994-03-16	1994-04-27	Scherer Ltd R P	Delivery systems for hydrophobic drugs

1996
- 1996-04-26 GB GBGB9608719.2A patent/GB9608719D0/en active Pending
1997
- 1997-04-25 ZA ZA9703653A patent/ZA973653B/xx unknown
- 1997-04-28 EP EP97920854A patent/EP0904064B1/de not_active Expired - Lifetime
- 1997-04-28 PT PT97920854T patent/PT904064E/pt unknown
- 1997-04-28 AT AT97920854T patent/ATE207346T1/de active
- 1997-04-28 DE DE69707669T patent/DE69707669T2/de not_active Expired - Lifetime
- 1997-04-28 JP JP53867897A patent/JP5088804B2/ja not_active Expired - Lifetime
- 1997-04-28 WO PCT/GB1997/001247 patent/WO1997040823A1/en not_active Ceased
- 1997-04-28 DK DK97920854T patent/DK0904064T3/da active
- 1997-04-28 AU AU27074/97A patent/AU2707497A/en not_active Abandoned
- 1997-04-28 ES ES97920854T patent/ES2164339T3/es not_active Expired - Lifetime
- 1997-04-28 KR KR1019980708569A patent/KR100511133B1/ko not_active Expired - Lifetime

Also Published As

Publication number	Publication date
ES2164339T3 (es)	2002-02-16
EP0904064A1 (de)	1999-03-31
JP5088804B2 (ja)	2012-12-05
JP2000510458A (ja)	2000-08-15
KR20000065025A (ko)	2000-11-06
DE69707669T2 (de)	2002-07-11
ATE207346T1 (de)	2001-11-15
EP0904064B1 (de)	2001-10-24
WO1997040823A1 (en)	1997-11-06
DE69707669D1 (de)	2001-11-29
PT904064E (pt)	2002-02-28
DK0904064T3 (da)	2001-12-17
KR100511133B1 (ko)	2006-04-28
AU2707497A (en)	1997-11-19
GB9608719D0 (en)	1996-07-03

Publication	Publication Date	Title
ZA973653B (en)	1997-11-19	Pharmaceutical compositions.
US5532002A (en)	1996-07-02	Gelatin pharmaceutical formulations
US5738871A (en)	1998-04-14	Pharmaceutical formulations
NO20014719D0 (no)	2001-09-28	Orale farmasöytiske preparater inneholdende lang-kjedete triglyserider og lipofile overflateaktive midler
KR940018091A (ko)	1994-08-16	불포화 지방산을 포함하는 처방
NZ512287A (en)	2002-12-20	Pharmaceutical compositions comprising a lipophilic drug in a propylene glycol ester of a higher fatty acid carrier, where 60% of the ester is a monoester
NZ515911A (en)	2004-02-27	Implantable gel compositions and method of manufacture
CN101528196A (zh)	2009-09-09	用于生物利用性差的药物的自乳化组合物
ES2101574T3 (es)	1997-07-01	Composicion administrable por via oral apta para formar una microemulsion.
IL143604A0 (en)	2002-04-21	Dispersable concentrate for the delivery of cyclosporin
UY26303A1 (es)	2001-03-16	Composiciones farmacéuticas para administración oral y tópica
AU4862796A (en)	1996-08-27	Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
RU98105629A (ru)	2000-02-10	Препараты, содержащие циклоспорин, в виде капсул с мягким покрытием
SI9720010B (sl)	2009-10-31	Ciklosporin vsebujoči mehki kapsulni pripravki
AU4554597A (en)	1998-04-02	Formulations for topical use
IL122434A (en)	2003-07-06	Compositions of mixed colloidal particles in an aqueous environment for sustained delivery of bioactive agents and pharmaceutical preparations therewith
JPH11199493A (ja)	1999-07-27	皮膚外用剤組成物
MY130474A (en)	2007-06-29	Oral pharmaceutical compositions containing long-chain triglycerides and lipophilic surfactants
RU99106544A (ru)	2001-02-20	Косметическая композиция